To hear about similar clinical trials, please enter your email below
Trial Title:
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
NCT ID:
NCT05608200
Condition:
Hepatocellular Carcinoma Non-resectable
Conditions: Official terms:
Carcinoma
Carcinoma, Hepatocellular
Lenvatinib
Chlorotrianisene
Conditions: Keywords:
Hepatocellular Carcinoma
Lenvatinib
Sintilimab
Transarterial Chemoembolization
Study type:
Interventional
Study phase:
Phase 3
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Lenvatinib, sintilimab plus TACE
Description:
Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab
(200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated
if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will
be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered
on study when the other drug cause intolerable toxicity.
Arm group label:
Len-Sin-TACE
Intervention type:
Drug
Intervention name:
Lenvatinib plus TACE
Description:
Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd will be started at
3-7 days after the first TACE. TACE will be repeated if clinically indicated. The
interruption, dose reduction and discontinuation of lenvatinib depended on the presence
and severity of toxicities according to the drug directions.
Arm group label:
Len-TACE
Summary:
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab
plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with
advanced hepatocellular carcinoma (HCC).
Detailed description:
This is a multicenter, prospective and randomized controlled trial to evaluate the
efficacy and safety of Len-Sin-TACE versus Len-TACE for patient with advanced HCC.
427 patients with advanced HCC (CNLC IIIa-IIIb/BCLC C stage) will be enrolled in this
study. The patients will receive either Len-Sin or Len alone after first TACE using an
2:1 randomization scheme. In the Len-Sin arm, lenvatinib 12mg (body weight ≥60kg) or 8mg
(body weight <60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days
after the first TACE. In the the Len arm, lenvatinib 12mg (body weight ≥60kg) or 8mg
(body weight <60kg) P.O. qd will be started at 3-7 days after the first TACE.
TACE will be repeated if clinically indicated based on the evaluation of follow-up
laboratory and imaging examination. Lenvatinib will last until disease progresses,
intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other
circumstances that require termination of treatment, whichever occurs first. Sintilimab
will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal
of informed consent, loss of follow-up, death, or other circumstances that require
termination of treatment, whichever occurs first. In the Len-Sin arm, patients will be
allowed to have lenvatinib or sintilimab as a sigle agent and will be still considered on
study when the other drug cause intolerable toxicity.
The primary end point of this study is overall survival (OS). The secondary endpoints are
progression-free survival (PFS), time to progression (TTP), objective response rate
(ORR), disease control rate (DCR), and adverse events (AEs).
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Advanced HCC (BCLC stage C, or CNLC IIIa and IIIb ) with diagnosis confirmed by
histology/cytology or clinically
- Patients who have Tumor recurrence after surgical resection or ablation are allowed
to be included
- At least one measurable intrahepatic target lesion
- Child-Pugh class A/B
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 3 months
Exclusion Criteria:
- Obstructive portal vein tumor thrombus involving both the left and right portal vein
or main portal vein without collateral vessels
- Vascular invasion involving inferior vena cava
- Central nervous system metastasis
- Patients who received prior systemic therapy, immunotherapy, TACE, transcatheter
arterial radioembolization (TARE), transcatheter arterial embolization (TAE),
hepatic arterial infusion chemotherapy (HAIC) or radiation therapy for HCC
- History of organ and cell transplantation
- History of bleeding from esophageal and gastric varices
- History of hepatic encephalopathy
- hematologic examination: white blood cell count <3.0×10^9/L, platelets <50×10^9/L
- Prothrombin time prolongation ≥ 4s
- Severe organ (heart, lung, kidney) dysfunction
- History of malignancy other than HCC
- Active hepatitis B or C infection; hepatitis B virus (HBV) DNA > 1000 copies/ml;
hepatitis C virus (HCV) RNA > 1000 copies/ml. Those who possess the indicators lower
than the above criteria after nucleotide antiviral treatment can be enrolled
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
The Second Affiliated Hospital of Guangzhou Medical University
Address:
City:
Guangzhou
Zip:
510260
Country:
China
Status:
Recruiting
Contact:
Last name:
Kangshun Zhu, MD
Phone:
+86-20-34156205
Email:
zhksh010@126.com
Start date:
November 2, 2022
Completion date:
October 31, 2026
Lead sponsor:
Agency:
Second Affiliated Hospital of Guangzhou Medical University
Agency class:
Other
Source:
Second Affiliated Hospital of Guangzhou Medical University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05608200